In preclinical melanoma, ovarian, breast and bladder cancer models, targeting PI3K/Akt or Wnt, which control CD8+ T-cell infiltration and cytotoxicity and selectively inhibit Treg proliferation, enhances antitumor immunity and promotes tumor regression. This evidence concerns the gene CD8A and neoplasm.